Source 1review2022International Journal of Molecular Sciences
Toolkit/human opsins
human opsins
Taxonomy: Mechanism Branch / Component. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Human opsins are protein domains used as optogenetic tools in visual restoration strategies. The supplied evidence indicates that applying human opsins can improve light sensitivity and wavelength sensitivity in optogenetic systems, and places these tools within ongoing clinical translation for retinal therapy.
Usefulness & Problems
Why this is useful
Human opsins are useful in optogenetic therapy design because they are associated with improved light sensitivity and wavelength sensitivity, two core performance parameters for light-driven control in the retina. The evidence specifically situates them in visual restoration efforts where optogenetic tool choice is a key design element.
Source:
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Problem solved
This tool helps address the challenge of achieving effective optical responsiveness for visual restoration, particularly by improving sensitivity to light intensity and wavelength. The supplied evidence does not provide more specific molecular or cell-type-resolved problem definitions beyond retinal optogenetic therapy design.
Source:
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Published Workflows
Objective: Translate human-opsin optogenetic visual restoration toward phase I safety testing and clinically meaningful restoration of light sensitivity.
Why it works: The review argues that human opsins provide intrinsic amplification and adaptation at lower light levels than microbial channels, and that ON-bipolar targeting preserves retinal computations relevant to useful vision.
G-protein-coupled signal amplificationbleaching-based light adaptationretention of inner-retinal computations through ON-bipolar targetingAAV capsid engineeringpromoter-guided cell targetingphase I safety trial designfunctional low-vision endpoint selection
Stages
- 1.Actuator and targeting strategy selection(library_design)
The abstract compares actuator classes and cell targets to justify choosing human opsins and ON-bipolar targeting before translation.
Selection: Prefer human opsins and ON-bipolar targeting to obtain lower-light operation, adaptation, and preservation of inner-retinal computations.
- 2.Vector and promoter optimization for ON-bipolar expression(secondary_characterization)
Delivery and promoter choice are presented as key translational determinants for expressing opsins in ON bipolar cells.
Selection: Use engineered AAV capsids and GRM6 or L7 promoters that achieve broad ON-BP expression in rodents.
- 3.Early clinical safety and functional evaluation(confirmatory_validation)
The review explicitly proposes phase I safety trials with defined exposure budgets and functional endpoints to move the approach toward clinical translation.
Selection: Evaluate acceptable ocular safety and emerging efficacy using prospectively defined light-exposure budgets and low-vision functional endpoints.
Steps
- 1.Select human opsins over microbial channels for lower-light operationactuator strategy
Choose an actuator class with intrinsic amplification and adaptation suitable for room-light visual restoration.
Actuator choice determines irradiance requirements, adaptation behavior, and safety considerations before delivery strategy is optimized.
- 2.Pair engineered AAV capsids with GRM6 or L7 promoters for ON-bipolar targetingdelivery and expression targeting system
Enable ON-bipolar expression so that inner-retinal computations are retained.
After choosing the actuator strategy, delivery and promoter design are needed to place expression in the intended retinal cell class.
- 3.Run phase I safety trials with defined light-exposure budgets and low-vision functional endpointsclinical candidate
Assess whether human-opsin vectors show acceptable ocular safety and meaningful early efficacy in humans.
Clinical testing is proposed after actuator and delivery strategy selection because it is the higher-fidelity translational test of safety and function.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Component: A low-level protein part used inside a larger architecture that realizes a mechanism.
Mechanisms
light activationTechniques
Computational DesignTarget processes
No target processes tagged yet.
Input: Light
Implementation Constraints
The evidence indicates that use of human opsins occurs within optogenetic therapy designs that also require selection of target retinal cells and gene delivery systems. No specific construct design, chromophore requirement, expression system, promoter, or vector details are provided in the supplied material.
The supplied evidence does not identify which human opsins were used, their spectral peaks, signaling properties, kinetics, or quantitative performance gains. It also does not provide independent comparative data, construct architectures, or direct trial results for any specific human opsin-based tool.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Approval Evidence
1 source6 linked approval claimsfirst-pass slug human-opsins
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by ... applying human opsins
Source:
clinical translation statussupports
Multiple clinical trials of optogenetic therapy for visual restoration are ongoing.
Multiple clinical trials are currently ongoing, less than a decade after the first attempt at visual restoration using optogenetics.
Source:
design factor importancesupports
Optogenetic therapy design involves target retinal cell choice, optogenetic tools, and gene delivery systems as key elements.
This alternative gene therapy consists of multiple elements including the choice of target retinal cells, optogenetic tools, and gene delivery systems.
Source:
engineering improvementsupports
Engineering microbial opsins and applying human opsins have improved optogenetic tool performance in light sensitivity and wavelength sensitivity.
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Source:
genotype independencesupports
Optogenetic therapy is described as potentially valuable for late-stage retinal degeneration regardless of genotype.
Optogenetic therapy has great value in providing hope for visual restoration in late-stage retinal degeneration, regardless of the genotype.
Source:
optimization needsupports
Better post-treatment vision requires optimal choice of optogenetic tools and effective gene delivery to retinal cells.
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Source:
therapeutic promisesupports
Optogenetic therapy is presented as a promising approach for treatment of retinal degenerative diseases and visual restoration.
Optogenetics is a recent breakthrough in neuroscience, and one of the most promising applications is the treatment of retinal degenerative diseases.
Source:
Comparisons
Source-backed strengths
The cited evidence attributes improved light sensitivity and wavelength sensitivity to the application of human opsins in optogenetic systems. Human opsins are also discussed in the context of a field with multiple ongoing clinical trials for visual restoration, supporting translational relevance of this tool class.
Source:
the performance of optogenetic tools in terms of light and wavelength sensitivity have been improved by engineering microbial opsins and applying human opsins
Source:
To provide better post-treatment vision, the optimal choice of optogenetic tools and effective gene delivery to retinal cells is necessary.
Ranked Citations
- 1.